Worldwide, at least 30 million people are living with slogans. In spite of improved treatment options, patients with pre-fibrillation still suffer from stroke, develop heart failure, and die prematurely. On the initiative of the Competence Network, and the European Heart Rhythm Association (EHRA), an international expert group has now developed a plan to improve the quality of the treatment of pre-slurries. The AFNET / EHRA consensus report is published today in the journal EP Europace.
More than 70 experts from almost every continent participated in the conference and exchanged their experiences. "In view of the great diversity of health systems worldwide, the different countries can learn from each other and develop better models for the treatment of atrial fibrillation. We hope that this plan, which has been created by specialists from different parts of the world, will help to improve the treatment of squibs in Europe and the world, "said Prof. Gerhard Hindricks, President of EHRA.
Several million people in the world have unidentified and therefore untreated pre-fibrillation, combined with a high risk of stroke and death. The AFNET / EHRA Roadmap recommends the introduction of a large-scale pre-screening screening for over-65s and high-risk populations to enable early diagnosis and treatment of pre-fibrillation.
Anticoagulants (anticoagulant drugs for stroke prevention) can only be effective if taken regularly. Therefore, strategies must be defined to minimize disruption or discontinuation of anticoagulation therapy.
Enlightened patients
For a successful therapy of atrial fibrillation - the experts agree on this - all patients should be involved in the decisions about their treatment. The prerequisite for this is that the patients are well informed. In order to achieve this, the authors recommend to improve the availability of free information on pre-ventilations and associated complications and treatment options.
Patient-friendly initiatives, such as the EHRA-developed patient website, available in five European languages, are considered to be very helpful to the inclusion of the Patients. In addition, "patient reported outcomes" should be used to capture symptoms and consequences of pre-fibrillation from the patient's perspective.
Structured treatment
Adequate treatment of pre-fibrillated patients is complex. Prof. Andreas Gotte, member of the board, said: "Such a aid of pre-fibrillation should check that all patients are offered information based therapy." Therefore, the AFNET / EHRA Plan recommends a structured approach guided by interdisciplinary teams Of care plans for all vaccine patients. Improved therapy
Several million people in the world have unidentified and therefore untreated pre-fibrillation, combined with a high risk of stroke and death. The AFNET / EHRA Roadmap recommends the introduction of a large-scale pre-screening screening for over-65s and high-risk populations to enable early diagnosis and treatment of pre-fibrillation. Anticoagulants (anticoagulant drugs for stroke prevention) can only be effective if taken regularly. Therefore, strategies must be defined to minimize disruption or discontinuation of anticoagulation therapy.
The experts recommend the development of standards with which the quality and success of the pre-flax ablation can be measured uniformly. Frequently, the rhythm disturbance is not completely eliminated by an ablation. Further studies are needed to find the best treatment for patients with presumptive relapse after ablation.
Personalized treatment
Further research is needed to better understand the cellular and molecular mechanisms underlying the pre-fibrillation. The experts propose to evaluate genetic factors, specific biomarkers, and ECG parameters to identify different subtypes of atrial fibrillation in individual patients and to develop more targeted therapies.
For example, new biomarkers or ECG information could be used to better estimate the individual risk of anticoagulation in patients with a medium or low risk of stroke. At present, it is not yet known whether these patients benefit from anticoagulation therapy or not. Prof. A. John Camm, the future president of the EHRA and co-organizers of the Fifth AFNET / EHRA Conference, concludes: "We believe that the proposed research activities can aid to hone the treatment of atrial fibrillation and the treatment for many patients around the world to improve. There is an imperative need for long-term research funding to enable the implementation of sufficiently large studies
More than 70 experts from almost every continent participated in the conference and exchanged their experiences. "In view of the great diversity of health systems worldwide, the different countries can learn from each other and develop better models for the treatment of atrial fibrillation. We hope that this plan, which has been created by specialists from different parts of the world, will help to improve the treatment of squibs in Europe and the world, "said Prof. Gerhard Hindricks, President of EHRA.
Several million people in the world have unidentified and therefore untreated pre-fibrillation, combined with a high risk of stroke and death. The AFNET / EHRA Roadmap recommends the introduction of a large-scale pre-screening screening for over-65s and high-risk populations to enable early diagnosis and treatment of pre-fibrillation.
Anticoagulants (anticoagulant drugs for stroke prevention) can only be effective if taken regularly. Therefore, strategies must be defined to minimize disruption or discontinuation of anticoagulation therapy.
Enlightened patients
For a successful therapy of atrial fibrillation - the experts agree on this - all patients should be involved in the decisions about their treatment. The prerequisite for this is that the patients are well informed. In order to achieve this, the authors recommend to improve the availability of free information on pre-ventilations and associated complications and treatment options.
Patient-friendly initiatives, such as the EHRA-developed patient website, available in five European languages, are considered to be very helpful to the inclusion of the Patients. In addition, "patient reported outcomes" should be used to capture symptoms and consequences of pre-fibrillation from the patient's perspective.
Structured treatment
Adequate treatment of pre-fibrillated patients is complex. Prof. Andreas Gotte, member of the board, said: "Such a aid of pre-fibrillation should check that all patients are offered information based therapy." Therefore, the AFNET / EHRA Plan recommends a structured approach guided by interdisciplinary teams Of care plans for all vaccine patients. Improved therapy
Several million people in the world have unidentified and therefore untreated pre-fibrillation, combined with a high risk of stroke and death. The AFNET / EHRA Roadmap recommends the introduction of a large-scale pre-screening screening for over-65s and high-risk populations to enable early diagnosis and treatment of pre-fibrillation. Anticoagulants (anticoagulant drugs for stroke prevention) can only be effective if taken regularly. Therefore, strategies must be defined to minimize disruption or discontinuation of anticoagulation therapy.
The experts recommend the development of standards with which the quality and success of the pre-flax ablation can be measured uniformly. Frequently, the rhythm disturbance is not completely eliminated by an ablation. Further studies are needed to find the best treatment for patients with presumptive relapse after ablation.
Personalized treatment
Further research is needed to better understand the cellular and molecular mechanisms underlying the pre-fibrillation. The experts propose to evaluate genetic factors, specific biomarkers, and ECG parameters to identify different subtypes of atrial fibrillation in individual patients and to develop more targeted therapies.
For example, new biomarkers or ECG information could be used to better estimate the individual risk of anticoagulation in patients with a medium or low risk of stroke. At present, it is not yet known whether these patients benefit from anticoagulation therapy or not. Prof. A. John Camm, the future president of the EHRA and co-organizers of the Fifth AFNET / EHRA Conference, concludes: "We believe that the proposed research activities can aid to hone the treatment of atrial fibrillation and the treatment for many patients around the world to improve. There is an imperative need for long-term research funding to enable the implementation of sufficiently large studies
No comments:
Post a Comment
Note: only a member of this blog may post a comment.